March 7, 2024
The Tax Cuts and Jobs Act (TCJA) of 2017 brought significant changes to how businesses treat research and development (R&D) expenses, impacting, among other things, how the insurance industry approaches internal software development. These changes, specifically affecting Section 174 of the Internal Revenue Code (IRC), took effect at the beginning of 2022 and continue to be relevant today.
Previously, for tax purposes, insurance companies could deduct the full cost of developing internal software used for claims processing, customer enrollment, and other core functions in the year those costs were incurred. However, the TCJA amended Section 174, requiring most R&D expenses, including qualified software development, to be capitalized for tax purposes and amortized over five years (fifteen years for foreign expenditures).
While the impact might vary depending on the scale and frequency of internal software development activities, insurance companies need to be aware of changes to compliance requirements and explore options to adapt.
Consider the following:
Under the new capitalization requirements, determining the difference between software development and maintenance/bug fixes has become an important exercise, as only qualified software development falls under the new Section 174 rules. For book purposes, while not requiring the capitalization of research and experimentation expenditures, GAAP standards allow for the capitalization of significant development efforts[1] that lead to new features or enhanced functionality, while expensing minor fixes and maintenance activities. For statutory accounting purposes, all software development costs are expensed unless the cost is directly related to operating system software, which is the only type of software that can be capitalized and depreciated in accordance with SSAP No. 16R –Electronic Data & Processing Software.
It is important to keep detailed records of development activities, maintenance logs, and descriptions of changes. This documentation can be crucial for justifying the accounting treatment. Some companies set minimum thresholds (e.g., based on cost or scope of change) to aid in differentiating development from maintenance.
As of March 7, 2024, despite bipartisan efforts in both chambers of Congress, there has been little progress in addressing the recent changes to Section 174.
In January 2024, the House of Representatives passed the American Innovation and Jobs Act (H.R. 2267)[2], which would retroactively repeal the Section 174 capitalization requirements for research and development expenses. This bill was sent to the Senate where it has lost most of its momentum.
The Senate, however, has a companion bill, the American Innovation and R&D Competitiveness Act (S. 866)[3], which also aims to repeal Section 174 but has not yet been voted on. While the House passing their version of a repeal is a significant development, the Senate still needs to vote on its corresponding bill, and even if it passes, both chambers would need to reconcile any differences before it reaches the President's desk for potential signature.
For now, any potential adjustments to Section 174 remain uncertain. It is important to understand the law as it is, the potential for changes to the law, and current compliance requirements. Let us know if we can be of any assistance.
[1] Accounting Standards Codification (ASC) 350-40
[2] https://www.congress.gov/bill/117th-congress/house-bill/2267
[3] https://www.congress.gov/bill/118th-congress/senate-bill/866?s=1&r=73